About Regenfro Co
Regenfro Co is a company based in Kyoto (Japan) founded in 2019 by Kenji Osafune. Regenfro Co has raised $28.88 million across 2 funding rounds from investors including Sumitomo Mitsui Banking Corporation, MITSUI CHEMICALS and Shimadzu Corporation. Regenfro Co operates in a competitive market with competitors including Esprit Pharma, Lipella, Kissei Pharmaceutical, NEXT Life Sciences and TheraVida, among others.
- Headquarter Kyoto, Japan
- Founders Kenji Osafune
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$28.88 M (USD)
in 2 rounds
-
Latest Funding Round
$16.8 M (USD), Series B
Oct 07, 2024
-
Investors
Sumitomo Mitsui Banking Corporation
& 20 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Regenfro Co
Regenfro Co has successfully raised a total of $28.88M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $16.8 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Regenfro Co
Regenfro Co has secured backing from 21 investors, including venture fund and institutional investors. Prominent investors backing the company include Sumitomo Mitsui Banking Corporation, MITSUI CHEMICALS and Shimadzu Corporation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital services are provided to support startups and innovation.
|
Locked | Locked | Locked | |
|
Venture capital fund focused on growth stage companies
|
Locked | Locked | Locked | |
|
VC firm investing in Japan and the US
|
Locked | Locked | Locked |
Investor details for Regenfro Co
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Regenfro Co
Investment portfolio details for Regenfro Co
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Regenfro Co
Detailed financials for Regenfro Co
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Regenfro Co Comparisons
Peer comparison for Regenfro Co
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Regenfro Co
Regenfro Co operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Esprit Pharma, Lipella, Kissei Pharmaceutical, NEXT Life Sciences and TheraVida, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Develop drugs for genitourinary (GU) disorders
|
|
| Locked | Locked | Locked |
Lipid-based therapies for common bladder syndromes are developed.
|
|
| Locked | Locked | Locked |
Therapies for renal diseases and urology-related anemia are developed.
|
|
| Locked | Locked | Locked |
Male contraception procedures are developed via Vasalgel technology.
|
|
| Locked | Locked | Locked |
Clinical stage biopharma company developing drugs for urology and central nervous system disorders
|
Detailed competitors of Regenfro Co
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Regenfro Co
Complete news archive for Regenfro Co
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Regenfro Co
Regenfro Co was founded in 2019 and raised its 1st funding round 3 years after it was founded.
Regenfro Co is headquartered in Kyoto, Japan. It is registered at Kyoto, Kyoto Prefecture, Japan.
Akifumi Morinaka is the current CEO of Regenfro Co.
Regenfro Co is a funded company, having raised a total of $28.88M across 2 funding rounds to date.
Developer of therapeutics to treat renal diseases. The company has developed stem cell-based regenerative therapeutic products such as patent-pending nephron progenitor cells for renal cells, patented erythropoietin-producing cells for renal anemia, and urethroplasty for the development of kidney organoids.
Regenfro Co's top competitors include Lipella, Kissei Pharmaceutical and Esprit Pharma.
Regenfro Co has 21 investors. Key investors include Sumitomo Mitsui Banking Corporation, MITSUI CHEMICALS, Shimadzu Corporation, Asahi Kasei, and m3.com.